Please login to the form below

Not currently logged in
Email:
Password:

RNAi

This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.

Alnylam claims first RNAi approval from FDA for patisiran

Alnylam claims first RNAi approval from FDA for patisiran

Alnylam claims first RNAi approval from FDA for patisiran. After years of ups and downs, triumph for gene-silencing tech. ... RNAi drugs are used to block gene expression, binding to the messenger RNA that corresponds to a defective gene and switching

Latest news

  • The year of the blockbuster The year of the blockbuster

    UK, the projected blockbuster list includes four biologicals, one  RNAi-based drug, one vaccine  and six small molecules. ... It is expected to become the first FDA-approved RNAi therapeutic following Alnylam’s completion of its new drug application

  • Optimum wins Silence Therapeutics account Optimum wins Silence Therapeutics account

    London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    use to 140, 000 patients in its licensed territories – but particularly for Alnylam which has seen its RNAi platform come under scrutiny in recent months.

  • Boehringer bolsters NASH pipeline with $201m Dicerna deal Boehringer bolsters NASH pipeline with $201m Dicerna deal

    Dicerna is a US specialist in RNA interference (RNAi), a technique that switches off messenger RNA associated with specific genes and prevents them from generating their corresponding proteins.

  • Alnylam takes off on APOLLO trial results Alnylam takes off on APOLLO trial results

    APOLLO showed that Alnylam's lead RNAi therapy patisiran is effective as a treatment for the rare disorder hereditary ATTR amyloidosis with polyneuropathy , and critically was well-tolerated by patients, sparking ... the RNAi drug showed significant

More from news
Approximately 6 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Boosting pharma’s metabolic rate Boosting pharma’s metabolic rate

    New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.

  • Deal Watch September 2016 Deal Watch September 2016

    800. Arrowhead / Amgen. Licences. 2 agreements to develop and commercialise RNAi therapies in CVS disease, upfront payments of $35m, $21.5m in equity plus $617m in option payments. ... 95. Geron / J&J. Licence. Exclusive worldwide rights to Geron's

  • Pharma deals during January 2014 Pharma deals during January 2014

    Our table includes four RNAi-based deals, so are we seeing a resurgence of interest in this field? ... The deal comprised a range of RNAi assets including pre-clinical candidates, IP and delivery technologies.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Bruce Peacock joins Dicerna from Ophthotech Bruce Peacock joins Dicerna from Ophthotech

    Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics